The Role of Resolvins, Protectins and Marensins in Non-Alcoholic Fatty Liver Disease (NAFLD)

被引:16
作者
Maciejewska-Markiewicz, Dominika [1 ]
Stachowska, Ewa [1 ]
Hawrylkowicz, Viktoria [1 ]
Stachowska, Laura [1 ]
Prowans, Piotr [2 ]
机构
[1] Pomeranian Med Univ, Dept Human Nutr & Metabol, PL-70204 Szczecin, Poland
[2] Pomeranian Med Univ, Clin Plast Endocrine & Gen Surg, PL-72009 Police, Poland
关键词
NAFLD; n-3; PUFA; resolvins; protectins; marensins; LEUKOTRIENE A(4) HYDROLASE; ANTIINFLAMMATORY ACTIONS; RESOLUTION; MEDIATORS; ACID; D1; INFLAMMATION; STEATOSIS; OMEGA-3-FATTY-ACIDS; ACCUMULATION;
D O I
10.3390/biom11070937
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Increased triacylglycerols' (TAG) synthesis, insulin resistance, and prolonged liver lipid storage might lead to the development of non-alcoholic fatty liver disease (NAFLD). Global prevalence of NAFLD has been estimated to be around 25%, with gradual elevation of this ratio along with the increased content of adipose tissue in a body. The initial stages of NAFLD may be reversible, but the exposition to pathological factors should be limited. As dietary factors greatly influence various disease development, scientists try to find dietary components, helping to alleviate the steatosis. These components include n-3 polyunsaturated (PUFA) fatty acids, especially eicosapentaenoic acid (EPA) and docosahexaenoic acids (DHA). This review focused on the role of resolvins, protectins and merensins in NAFLD.
引用
收藏
页数:9
相关论文
共 50 条
  • [41] Hypoxia and Non-alcoholic Fatty Liver Disease
    Isaza, Stephania C.
    del Pozo-Maroto, Elvira
    Dominguez-Alcon, Lucia
    Elbouayadi, Liliam
    Gonzalez-Rodriguez, Agueda
    Garcia-Monzon, Carmelo
    FRONTIERS IN MEDICINE, 2020, 7
  • [42] Macrophages and scavenger receptors in obesity-associated non-alcoholic liver fatty disease (NAFLD)
    Kragh Petersen, Sine
    Bilkei-Gorzo, Orsolya
    Govaere, Olivier
    Hartlova, Anetta
    SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2020, 92 (05)
  • [43] Precision Medicine in Fatty Liver Disease/Non-Alcoholic Fatty Liver Disease
    Valenzuela-Vallejo, Laura
    Sanoudou, Despina
    Mantzoros, Christos S.
    JOURNAL OF PERSONALIZED MEDICINE, 2023, 13 (05):
  • [44] New diagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD)
    Ali, Rafeeq
    Cusi, Kenneth
    ANNALS OF MEDICINE, 2009, 41 (04) : 265 - 278
  • [45] Agai improves non-alcoholic fatty liver disease (NAFLD) induced by fructose
    de Freitas Carvalho, Mayara Medeiros
    Teixeira Reis, Larissa Lelis
    Macedo Lopes, Juliana Marcia
    Lage, Nara Nunes
    da Costa Guerra, Joyce Ferreira
    Zago, Helena Porto
    Bonomo, Larissa de Freitas
    Pereira, Renata Rebeca
    de Lima, Wanderson Geraldo
    Silva, Marcelo Eustaquio
    Pedrosa, Maria Lucia
    NUTRICION HOSPITALARIA, 2018, 35 (02) : 318 - 325
  • [46] Diet and Non-Alcoholic Fatty Liver Disease: The Mediterranean Way
    Abenavoli, Ludovico
    Boccuto, Luigi
    Federico, Alessandro
    Dallio, Marcello
    Loguercio, Carmelina
    Di Renzo, Laura
    De Lorenzo, Antonino
    INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2019, 16 (17)
  • [47] Non-alcoholic Fatty Liver Disease
    Tan, Hui-Hui
    Chang, Jason Pik-Eu
    PROCEEDINGS OF SINGAPORE HEALTHCARE, 2010, 19 (01) : 36 - 50
  • [48] Factors predicting non-alcoholic steatohepatitis (NASH) and advanced fibrosis in patients with non-alcoholic fatty liver disease (NAFLD)
    Tasneem, Abbas Ali
    Luck, Nasir Hassan
    Majid, Zain
    TROPICAL DOCTOR, 2018, 48 (02) : 107 - 112
  • [49] Non-alcoholic fatty Liver disease
    Calderaro, Julien
    Zafrani, Elie Serge
    ANNALES DE PATHOLOGIE, 2010, 30 (06) : 413 - 420
  • [50] Non-alcoholic fatty liver disease
    Maurice, James
    Manousou, Pinelopi
    CLINICAL MEDICINE, 2018, 18 (03) : 245 - 250